CoChat

Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activities

The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.

Abstract

Recombinant human erythropoietin (rhEPO) is receiving increasing attention as a potential therapy for prevention of injury and restoration of function in nonhematopoietic tissues. However, the minimum effective dose required to mimic and augment these normal paracrine functions of erythropoietin (EPO) in some organs (e.g., the brain) is higher than for treatment of anemia. Notably, a dose-dependent risk of adverse effects has been associated with rhEPO administration, especially in high-risk groups, including polycythemia–hyperviscosity syndrome, hypertension, and vascular thrombosis. Of note, several clinical trials employing relatively high dosages of rhEPO in oncology patients were recently halted after an increase in mortality and morbidity, primarily because of thrombotic events. We recently identified a heteromeric EPO receptor complex that mediates tissue protection and is distinct from the homodimeric receptor responsible for the support of erythropoiesis. Moreover, we developed receptor-selective ligands that provide tools to assess which receptor isoform mediates which biological consequence of rhEPO therapy. Here, we demonstrate that rhEPO administration in the rat increases systemic blood pressure, reduces regional renal blood flow, and increases platelet counts and procoagulant activities. In contrast, carbamylated rhEPO, a heteromeric receptor-specific ligand that is fully tissue protective, increases renal blood flow, promotes sodium excretion, reduces injury-induced elevation in procoagulant activity, and does not effect platelet production. These preclinical findings suggest that nonerythropoietic tissue-protective ligands, which appear to elicit fewer adverse effects, may be especially useful in clinical settings for tissue protection.

Overview

Integrity signals

Registry

Crossref · 10.1073/pnas.0601377103

Cites

62 of 62 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 62 references

Research works printed but not linked: 7

  1. D. Santini, B. Vincenzi, A. La Cesa, V. Virzi, F. Navajas, V. Malafarina, G. Dicuonzo, R. Cassandro, V. Esposito, V. Montesarchio, et al. Anticancer Res 25, 669–674 (2005).
  2. 10.1002/1097-0320(20000701)40:3<173::AID-CYTO1>3.0.CO;2-L · doi:10.1002/1097-0320(20000701)40:3<173::aid-cyto1>3.0.co;2-l
  3. N. D. Vaziri, X. J. Zhou, J. Smith, F. Oveisi, K. Baldwin, R. E. Purdy Am. J. Physiol 269, F838–F845 (1995).
  4. M. Nowicki J. Hum. Hypertens 9, 81–88 (1995).
  5. A. Lin, J. Ryu, D. Harvey, B. Sieracki, S. Scudder, T. Wun Gynecol. Oncol, 2006).
  6. 10.1016/S0008-6363(96)00066-1 · doi:10.1016/s0008-6363(96)00066-1 · Paper page
  7. 10.1093/oxfordjournals.ndt.a027361 · doi:10.1093/oxfordjournals.ndt.a027361 · Paper page

Metadata

Authors
Coleman, T. R., Westenfelder, C., Tögel, F. E., Yang, Y., Hu, Z., Swenson, L., Leuvenink, H. G. D., Ploeg, R. J., d’Uscio, L. V., Katusic, Z. S., Ghezzi, P., Zanetti, A., Kaushansky, K., Fox, N. E., Cerami, A., & Brines, M.
Affiliations
  • Verona Pharma (United Kingdom) (GB)
  • University of Utah (US)
  • Departments of Medicine and Physiology, University of Utah and Veterans Affairs Medical Centers, Salt Lake City, UT 84148;
  • University of Groningen (NL)
  • Mayo Clinic (US)
  • University of Groningen, 9700 AB, Groningen, The Netherlands;
  • Mario Negri Institute for Pharmacological Research (IT)
  • University of California San Diego (US)
Venue
Proceedings of the National Academy of Sciences
Published
2006-04-11
Volume
103
Issue
15
Pages
5965-5970
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W2106292297
Cited by
127
References
62
Citations by year
2026: 1 · 2025: 2 · 2024: 2 · 2023: 1 · 2022: 1 · 2021: 3 · 2020: 2 · 2019: 6 · 2018: 4 · 2017: 4 · 2016: 5 · 2015: 3 · 2014: 5 · 2013: 9 · 2012: 7
FWCI
9.24
Type
journal article
Language
en
Open access
closed
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion)
  • PubMed (publishedVersion)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion)
  • CINECA IRIS Institutional Research information system (University of Urbino) (submittedVersion)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
Funders
National Cancer Institute (R01CA031615)
Topics
  • Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
  • Life Sciences › Immunology and Microbiology › Immunology › Biosimilars and Bioanalytical Methods
  • Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
Keywords
recombinant human erythropoietin, carbamylated erythropoietin, erythropoietin receptor, heteromeric receptors, procoagulant activity, platelet count, blood pressure, renal blood flow, sodium excretion, tissue protection, thrombosis, dose-dependent adverse effects, paracrine effects
MeSH terms
Animals, Blood Coagulation, Blood Pressure, Bone Marrow Cells, Cell Line, Coagulants, Endothelium, Vascular, Erythropoietin, Hematopoiesis, Hemodynamics, Humans, Renal Circulation, Stem Cells, Umbilical Veins, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activities. https://app.cochat.ai/papers/10.1073/pnas.0601377103
The paper
Coleman, T. R., Westenfelder, C., Tögel, F. E., Yang, Y., Hu, Z., Swenson, L., Leuvenink, H. G. D., Ploeg, R. J., d’Uscio, L. V., Katusic, Z. S., Ghezzi, P., Zanetti, A., Kaushansky, K., Fox, N. E., Cerami, A., & Brines, M. (2006). Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activities. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.0601377103

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.